Literature DB >> 12552431

Treatment history and treatment dose are important determinants of sulfadoxine-pyrimethamine efficacy in children with uncomplicated malaria in Western Kenya.

Dianne J Terlouw1, Jeanne M Courval, Margarette S Kolczak, Oren S Rosenberg, Aggrey J Oloo, Piet A Kager, Altaf A Lal, Bernard L Nahlen, Feiko O ter Kuile.   

Abstract

This study retrospectively studied amendable determinants of sulfadoxine-pyrimethamine (SP) efficacy involving 2869 treatments among 1072 Kenyan children <5 years old who had uncomplicated malaria. The dose was based on age: one-quarter tablet was given to infants <1 year old, one-half tablet was given to 1-3-year-old children, and a full tablet was given to 4-year-old children. Only 23.5% received the internationally recommended target dose of 25/1.25 mg of SP per kg of body weight. SP intake in the previous 15-35 days (adjusted relative risk, 1.67; 95% confidence interval, 1.35-2.07) and low SP dose (<27.5/1.375 mg/kg) (adjusted relative risk, 1.58; 95% confidence interval, 1.17-2.13) explained 38% of parasitological treatment failures by day 7. Patients with recent SP intake are likely to have recrudescent infections and may need close follow-up if treated with SP or alternative treatment. Applying our weight-for-age data to 31 existing age-based SP dose recommendations predicted that 22 of them would result in underdosing of >25% of children <5 years. Many age-based dose recommendations need urgent revision, because SP is increasingly used as first-line treatment in sub-Saharan Africa.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12552431     DOI: 10.1086/367705

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  17 in total

1.  Seaweeds as a source of lead compounds for the development of new antiplasmodial drugs from South East coast of India.

Authors:  Sundaram Ravikumar; Samuel Jacob Inbaneson; Palavesam Suganthi
Journal:  Parasitol Res       Date:  2010-12-29       Impact factor: 2.289

Review 2.  Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination.

Authors:  Teun Bousema; Chris Drakeley
Journal:  Clin Microbiol Rev       Date:  2011-04       Impact factor: 26.132

3.  Mangrove plants as a source of lead compounds for the development of new antiplasmodial drugs from South East coast of India.

Authors:  Sundaram Ravikumar; Samuel Jacob Inbaneson; Palavesam Suganthi; Malaiyandi Venkatesan; Andy Ramu
Journal:  Parasitol Res       Date:  2010-12-01       Impact factor: 2.289

4.  The quality of sulfadoxine-pyrimethamine prescriptions, counselling and drug-dispensing practices, for children in Kenya.

Authors:  D Zurovac; S A Ochola; B Midia; R W Snow
Journal:  Ann Trop Med Parasitol       Date:  2005-04

5.  Sulfadoxine-pyrimethamine in treatment of malaria in Western Kenya: increasing resistance and underdosing.

Authors:  Dianne J Terlouw; Bernard L Nahlen; Jeanne M Courval; Simon K Kariuki; Oren S Rosenberg; Aggrey J Oloo; Margarette S Kolczak; William A Hawley; Altaf A Lal; Feiko O ter Kuile
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

6.  Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda.

Authors:  Julia Mwesigwa; Sunil Parikh; Bryan McGee; Polina German; Troy Drysdale; Joan N Kalyango; Tamara D Clark; Grant Dorsey; Niklas Lindegardh; Anna Annerberg; Philip J Rosenthal; Moses R Kamya; Francesca Aweeka
Journal:  Antimicrob Agents Chemother       Date:  2009-10-19       Impact factor: 5.191

7.  Amodiaquine dosage and tolerability for intermittent preventive treatment to prevent malaria in children.

Authors:  M Cairns; B Cisse; C Sokhna; C Cames; K Simondon; E H Ba; J-F Trape; O Gaye; B M Greenwood; P J M Milligan
Journal:  Antimicrob Agents Chemother       Date:  2010-01-11       Impact factor: 5.191

8.  Evolution of resistance to sulfadoxine-pyrimethamine in Plasmodium falciparum.

Authors:  Michelle L Gatton; Laura B Martin; Qin Cheng
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

9.  Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drug-resistant malaria.

Authors:  R N Price; A R Hasugian; A Ratcliff; H Siswantoro; H L E Purba; E Kenangalem; N Lindegardh; P Penttinen; F Laihad; E P Ebsworth; N M Anstey; E Tjitra
Journal:  Antimicrob Agents Chemother       Date:  2007-09-10       Impact factor: 5.191

10.  Efficacy of sulphadoxine-pyrimethamine with or without artesunate for the treatment of uncomplicated Plasmodium falciparum malaria in southern Mozambique: a randomized controlled trial.

Authors:  Elizabeth N Allen; Francesca Little; Tunisio Camba; Yasmin Cassam; Jaishree Raman; Andrew Boulle; Karen I Barnes
Journal:  Malar J       Date:  2009-06-26       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.